Pharma

SubsectorHealthcare

Minutes holds 12 developments and 2 deals in Pharma, across 16 companies, recorded from September 2026.

Intelligence

Related subsectors

Deals in Pharma

More in Deals →

Deals in Pharma
Company	Deal	Amount	Counterparties	Date ↓	Status
Chr. Olesen SynthesisPharma	Buyout	Undisclosed	Acquired by SamfaraSold by Chr. Olesen, Signet Healthcare Partners	2 Oct	Closed
Summit TherapeuticsPharma	FundingEquity investment with alliance	$2B	Investors AstraZeneca	29 Sep	Announced

Chr. Olesen SynthesisUndisclosed
Buyout by Samfara +2
Pharma · 2 Oct · Closed
Summit Therapeutics$2B
FundingEquity investment with alliance, with AstraZeneca
Pharma · 29 Sep · Announced

Showing 1–2 of 2

Activity

Developments in Pharma

Past 3 months in Activity →

Aurora Cannabis again tells shareholders to reject Curaleaf's revised hostile bid

M&AAurora Cannabis, Curaleaf, +1Pharma14 OctPR Newswire

GSK to invest more than $800 million in a Pennsylvania manufacturing hub

ExpansionGSKPharma13 OctManufacturing Dive

EU accepts Sanofi's concessions to end vaccine marketing antitrust probe

RegulatorySanofi, European Commission, +1Pharma14 OctThe Wall Street Journal

Lonza raises its medium-term ambitions

ResultsLonzaPharma14 OctThe Wall Street Journal

Pfizer reports Phase 2 eczema data and moves tilrekimig into later trials

PfizerPharma1 OctBioPharma Dive

Investor Samfara buys Danish drug ingredient maker Chr. Olesen Synthesis

Deal · BuyoutSamfara, Chr. Olesen Synthesis, +1Pharma2 OctPR Newswire +4

Sanofi and Regeneron expand antibody deal with $1 billion upfront

PartnershipSanofi, Regeneron Pharmaceuticals, +1Pharma1 OctStatnews +1

Bristol Myers adds liver monitoring to Phase 3 trial of fibrosis drug admilparant

Bristol Myers SquibbPharma30 SepBioPharma Dive

AstraZeneca invests $2 billion in cancer drug developer Summit Therapeutics

Deal · FundingSummit TherapeuticsPharma29 SepBioPharma Dive +1

Novo Nordisk licenses Hengrui's experimental weekly obesity pill for up to $2.6 billion

PartnershipNovo Nordisk, Hengrui Pharma, +1Pharma29 SepBioPharma Dive +3

Jazz Pharmaceuticals buys Actio Biosciences for $820 million upfront

Deal · AcquisitionJazz Pharmaceuticals, Actio Biosciences, +1Pharma15 SepPR Newswire

Novo Nordisk rebrands as Novo in its obesity fight with Eli Lilly

StrategyNovo NordiskPharma14 SepCNBC